AnonShop – FDA Warning Letter

The FDA issued a Warning Letter to AnonShop for offering products, specifically opioids, for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The agency determined that AnonShop introduces unapproved new drugs and misbranded drugs into interstate commerce, violating sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act. The letter highlights the severe public health risk, particularly amid the U.S. opioid epidemic, noting that unapproved opioids lack assurances of safety and effectiveness and may be contaminated or counterfeit. The products are considered unapproved new drugs under sections 201(g) and 201(p) because they are not generally recognized as safe and effective and lack FDA approval. Furthermore, these drugs are misbranded under section 502(f)(1) of the FD&C Act as they fail to bear adequate directions for use, being prescription drugs not safe for self-diagnosis by a layperson. AnonShop is required to immediately cease offering violative drugs and take prompt action to correct all identified violations. The firm must notify the FDA in writing within 10 working days of the steps taken or planned to correct the violations and prevent recurrence. Failure to comply may result in regulatory actions such as seizure or injunction.